Remogliflozin etabonate
依碳酸瑞格列净
Report date: 2022/01/17 12:14:22
NME
Base Information
Drug NameRemogliflozin etabonate
Drug Alias Name +[10]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved Indications
Approved Indications in ChinaN/A
Original Approved Country/Territory
Original Approved Date2019/04/30
Country/Territory +[23]
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesKissei Pharmaceutical Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesGlenmark Pharmaceuticals Ltd
Inactive CompaniesBhv PharmaGlaxosmithkline Plc
Active Indications
Inactive Indications